DaVita Inc. (NYSE:DVA) Given Average Recommendation of “Hold” by Brokerages

DaVita Inc. (NYSE:DVA) has been given an average rating of “Hold” by the eight brokerages that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $199.1667.

A number of research firms recently weighed in on DVA. Barclays increased their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Truist Financial increased their price target on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a research note on Friday, May 8th. TD Cowen increased their price target on DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research note on Monday.

DaVita Trading Up 3.2%

DVA opened at $198.19 on Wednesday. DaVita has a 1-year low of $101.00 and a 1-year high of $202.69. The stock’s fifty day simple moving average is $173.05 and its 200 day simple moving average is $144.47. The stock has a market cap of $12.72 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the prior year, the business earned $2.00 EPS. The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts forecast that DaVita will post 15.07 earnings per share for the current year.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This represents a 27.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its position in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after purchasing an additional 28,739 shares in the last quarter. Cerity Partners LLC grew its position in shares of DaVita by 7.0% during the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock worth $376,000 after purchasing an additional 172 shares in the last quarter. Bank of Nova Scotia grew its position in shares of DaVita by 3.8% during the 2nd quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock worth $686,000 after purchasing an additional 176 shares in the last quarter. Finally, Natixis grew its position in shares of DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company’s stock worth $1,039,000 after purchasing an additional 3,264 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.